ticlopidine has been researched along with Genetic Predisposition in 43 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS)." | 9.22 | Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes. ( Bian, S; Dong, P; Yang, X, 2016) |
| "Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well." | 8.88 | The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 7.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| "Bleeding is one of the possible adverse events during clopidogrel therapy." | 7.88 | Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018) |
| "The anti-platelet drug clopidogrel has been shown to modulate adhesion molecule and cytokine expression, both playing an important role in the pathogenesis of atherosclerosis." | 7.83 | Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. ( Ensminger, SM; Gebhardt, J; Heim, C; Jacobi, J; Ramsperger-Gleixner, M; Weyand, M, 2016) |
| "We aimed to investigate the association of aspirin and/or clopidogrel low response with -455G/A polymorphism of β-fibrinogen in patients with acute coronary syndrome (ACS)." | 7.80 | Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome. ( Bakirci, EM; Borekci, A; Kalkan, K; Karakoyun, S; Sevimli, S; Topcu, S; Vançelik, S, 2014) |
| "BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS)." | 5.22 | Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes. ( Bian, S; Dong, P; Yang, X, 2016) |
| "Clopidogrel is recommended in addition to aspirin to prevent atherothrombotic events in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI)." | 5.16 | The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. ( de la Peña, NC; Isordia-Salas, I; Olalde-Román, MJ; Santiago-Germán, D; Valencia-Sánchez, JS, 2012) |
| "Some patients with acute coronary syndromes and/or who are undergoing percutaneous coronary interventions (PCI) remain at risk for cardiovascular events despite antiplatelet treatment with clopidogrel." | 4.89 | Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests. ( Valgimigli, M, 2013) |
| "Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well." | 4.88 | The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 3.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| "Bleeding is one of the possible adverse events during clopidogrel therapy." | 3.88 | Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018) |
| "The anti-platelet drug clopidogrel has been shown to modulate adhesion molecule and cytokine expression, both playing an important role in the pathogenesis of atherosclerosis." | 3.83 | Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. ( Ensminger, SM; Gebhardt, J; Heim, C; Jacobi, J; Ramsperger-Gleixner, M; Weyand, M, 2016) |
| "Using a mouse model of intra-abdominal sepsis and acute lung injury, we investigated the role of the P2Y12 receptor in neutrophil migration and lung inflammation in P2Y12 null mice and in mice pretreated with the P2Y12 antagonist clopidogrel." | 3.83 | P2Y12 Receptor Modulates Sepsis-Induced Inflammation. ( Kilpatrick, LE; Kunapuli, SP; Liverani, E; Rico, MC; Tsygankov, AY, 2016) |
| "To assess the association of genetic polymorphisms of CYP2C19*2,*3,*17 with the recurrence risk of ischemic stroke during clopidogrel prevention in ethnic Han Chinese from Fujian Province." | 3.81 | [Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian]. ( Fang, L; Huang, H; Lin, M; Wang, N; Yang, Z; Zhao, Y, 2015) |
| "We aimed to investigate the association of aspirin and/or clopidogrel low response with -455G/A polymorphism of β-fibrinogen in patients with acute coronary syndrome (ACS)." | 3.80 | Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome. ( Bakirci, EM; Borekci, A; Kalkan, K; Karakoyun, S; Sevimli, S; Topcu, S; Vançelik, S, 2014) |
| "The aim of this study was to evaluate the association of PON1 genetic variants with the susceptibility to coronary artery disease (CAD) and with the clinical endpoints in aspirin and clopidogrel (dual antiplatelet therapy)-treated Han Chinese patients with CAD after percutaneous coronary intervention (PCI)." | 3.79 | Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. ( Chen, JY; Kang, YH; Lai, WH; Lao, HY; Li, XX; Wu, H; Yu, XY; Zhong, SL, 2013) |
| "The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel." | 3.79 | Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. ( Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G, 2013) |
| "This case-control study identified 3 genes (CYP2C19, ABCB1, and ITGB3) and 2 clopidogrel-related factors (loading dose and proton pump inhibitors) that were independently associated with early stent thrombosis." | 3.77 | Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. ( Allanic, F; Barthélémy, O; Beygui, F; Cayla, G; Collet, JP; de la Briolle, A; Gruel, Y; Huerre, Y; Hulot, JS; Montalescot, G; O'Connor, SA; Pathak, A; Scott, SA; Silvain, J; Vignalou, JB, 2011) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| "Substantial evidence suggests that genetic predisposition plays a vital role in the physiopathology of this complex disease." | 2.55 | Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine. ( El Amri, H; Zaiou, M, 2017) |
| " Hyporesponsive patients might benefit from different dosing strategies or additional antiplatelet therapies." | 2.44 | Investigating the mechanisms of hyporesponse to antiplatelet approaches. ( Angiolillo, D; Bates, E; Berger, PB; Bhatt, D; Braunwald, E; Cannon, CP; Furman, MI; Gurbel, P; Michelson, AD; Peterson, E; Wiviott, S, 2008) |
| " Confounders included gender, age, smoking status, dosage of aspirin and clopidogrel, and BMI." | 1.51 | Two common mutations within CYP2C19 affected platelet aggregation in Chinese patients undergoing PCI: a one-year follow-up study. ( Chen, W; Fu, Y; Li, W; Liu, Z; Tang, Y; Wang, W; Wang, Z; Zhang, X; Zhou, Z, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (11.63) | 29.6817 |
| 2010's | 38 (88.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Su, J | 2 |
| Yu, Q | 2 |
| Zhu, H | 1 |
| Li, X | 2 |
| Cui, H | 2 |
| Du, W | 2 |
| Ji, L | 1 |
| Tong, M | 2 |
| Zheng, Y | 1 |
| Xu, H | 1 |
| Zhang, J | 1 |
| Zhu, Y | 1 |
| Xia, Y | 1 |
| Liu, T | 1 |
| Yao, Q | 1 |
| Yang, J | 1 |
| Chen, X | 2 |
| Yu, J | 1 |
| Zhong, Z | 1 |
| Hou, J | 1 |
| Zhang, Q | 1 |
| Li, B | 1 |
| Li, C | 1 |
| Liu, Z | 2 |
| Yang, M | 1 |
| Zhong, W | 1 |
| He, X | 1 |
| Wu, H | 2 |
| Zhong, M | 1 |
| Zhao, P | 1 |
| Novkovic, M | 1 |
| Matic, D | 1 |
| Kusic-Tisma, J | 1 |
| Antonijevic, N | 1 |
| Radojkovic, D | 1 |
| Rakicevic, L | 1 |
| Wu, Y | 1 |
| Yu, H | 1 |
| Tang, HQ | 1 |
| Su, Y | 1 |
| Shi, TL | 1 |
| Liu, S | 1 |
| Xia, Q | 1 |
| Xu, DJ | 1 |
| Parker, WAE | 1 |
| Eriksson, N | 1 |
| Becker, RC | 2 |
| Voora, D | 1 |
| Åkerblom, A | 1 |
| Himmelmann, A | 1 |
| James, SK | 2 |
| Wallentin, L | 2 |
| Storey, RF | 1 |
| Wang, Z | 1 |
| Wang, W | 1 |
| Fu, Y | 1 |
| Chen, W | 1 |
| Li, W | 1 |
| Zhang, X | 1 |
| Tang, Y | 1 |
| Zhou, Z | 1 |
| Kang, YH | 1 |
| Lao, HY | 1 |
| Lai, WH | 1 |
| Li, XX | 1 |
| Yu, XY | 1 |
| Chen, JY | 1 |
| Zhong, SL | 1 |
| Tanboğa, IH | 1 |
| Can, MM | 1 |
| Ozkan, A | 1 |
| Tokgöz, HC | 1 |
| Akgün, T | 1 |
| Koca, F | 1 |
| Kurt, M | 1 |
| Kaymaz, C | 1 |
| Sevimli, S | 1 |
| Karakoyun, S | 1 |
| Bakirci, EM | 1 |
| Topcu, S | 1 |
| Kalkan, K | 1 |
| Borekci, A | 1 |
| Vançelik, S | 1 |
| Valgimigli, M | 1 |
| Liu, Y | 1 |
| Wang, Y | 1 |
| Song, H | 1 |
| Fei, X | 1 |
| Liu, J | 1 |
| Lin, S | 1 |
| Wang, J | 1 |
| Zheng, W | 1 |
| Zhong, J | 1 |
| Zhang, L | 1 |
| Xu, J | 1 |
| Heim, C | 1 |
| Gebhardt, J | 1 |
| Ramsperger-Gleixner, M | 1 |
| Jacobi, J | 1 |
| Weyand, M | 1 |
| Ensminger, SM | 1 |
| Wei, YQ | 1 |
| Wang, DG | 1 |
| Yang, H | 1 |
| Cao, H | 1 |
| Lin, M | 2 |
| Todaro, M | 1 |
| Chan, J | 1 |
| Churilov, L | 1 |
| Zhu, WS | 1 |
| Ramdave, S | 1 |
| Mitchell, PJ | 1 |
| Dowling, RJ | 1 |
| Kwan, P | 1 |
| Yan, B | 1 |
| Fang, L | 1 |
| Zhao, Y | 1 |
| Wang, N | 1 |
| Yang, Z | 1 |
| Huang, H | 1 |
| Liverani, E | 1 |
| Rico, MC | 1 |
| Tsygankov, AY | 1 |
| Kilpatrick, LE | 1 |
| Kunapuli, SP | 1 |
| Yang, HH | 1 |
| Chen, Y | 1 |
| Gao, CY | 1 |
| Li, RH | 1 |
| Stern, JA | 1 |
| Ho, V | 1 |
| Tablin, F | 1 |
| Harris, SP | 1 |
| Zaiou, M | 1 |
| El Amri, H | 1 |
| Dong, P | 1 |
| Yang, X | 1 |
| Bian, S | 1 |
| Nicoletti, P | 1 |
| Aithal, GP | 1 |
| Bjornsson, ES | 1 |
| Andrade, RJ | 1 |
| Sawle, A | 1 |
| Arrese, M | 1 |
| Barnhart, HX | 1 |
| Bondon-Guitton, E | 1 |
| Hayashi, PH | 1 |
| Bessone, F | 1 |
| Carvajal, A | 1 |
| Cascorbi, I | 1 |
| Cirulli, ET | 1 |
| Chalasani, N | 1 |
| Conforti, A | 1 |
| Coulthard, SA | 1 |
| Daly, MJ | 1 |
| Day, CP | 1 |
| Dillon, JF | 1 |
| Fontana, RJ | 1 |
| Grove, JI | 1 |
| Hallberg, P | 1 |
| Hernández, N | 1 |
| Ibáñez, L | 1 |
| Kullak-Ublick, GA | 1 |
| Laitinen, T | 1 |
| Larrey, D | 1 |
| Lucena, MI | 1 |
| Maitland-van der Zee, AH | 1 |
| Martin, JH | 1 |
| Molokhia, M | 1 |
| Pirmohamed, M | 1 |
| Powell, EE | 1 |
| Qin, S | 1 |
| Serrano, J | 1 |
| Stephens, C | 1 |
| Stolz, A | 1 |
| Wadelius, M | 1 |
| Watkins, PB | 1 |
| Floratos, A | 1 |
| Shen, Y | 1 |
| Nelson, MR | 1 |
| Urban, TJ | 1 |
| Daly, AK | 1 |
| Hayden, EC | 1 |
| Heo, JH | 1 |
| Kim, M | 1 |
| Sawada, T | 1 |
| Shinke, T | 1 |
| Shite, J | 1 |
| Honjo, T | 1 |
| Haraguchi, Y | 1 |
| Nishio, R | 1 |
| Shinohara, M | 1 |
| Toh, R | 1 |
| Ishida, T | 1 |
| Kawamori, H | 1 |
| Kozuki, A | 1 |
| Inoue, T | 1 |
| Hariki, H | 1 |
| Hirata, K | 1 |
| Harrington, RA | 1 |
| Lischke, S | 1 |
| Schneider, DJ | 1 |
| Komarov, AL | 1 |
| Panchenko, EP | 1 |
| Donnikov, AE | 1 |
| Shakhmatova, OO | 1 |
| Dzhalilova, GV | 1 |
| Iliushchenko, TA | 1 |
| Jeong, YH | 1 |
| Park, Y | 1 |
| Kim, IS | 1 |
| Kassimis, G | 1 |
| Davlouros, P | 1 |
| Xanthopoulou, I | 1 |
| Stavrou, EF | 1 |
| Athanassiadou, A | 1 |
| Alexopoulos, D | 1 |
| Cayla, G | 1 |
| Hulot, JS | 1 |
| O'Connor, SA | 1 |
| Pathak, A | 1 |
| Scott, SA | 1 |
| Gruel, Y | 1 |
| Silvain, J | 1 |
| Vignalou, JB | 1 |
| Huerre, Y | 1 |
| de la Briolle, A | 1 |
| Allanic, F | 1 |
| Beygui, F | 1 |
| Barthélémy, O | 1 |
| Montalescot, G | 1 |
| Collet, JP | 1 |
| Wiwanitkit, V | 1 |
| Luo, Y | 1 |
| Zhao, YT | 1 |
| Verdo, A | 1 |
| Qi, WG | 1 |
| Zhang, DF | 1 |
| Hu, B | 1 |
| Li, Y | 1 |
| Tang, HL | 1 |
| Hu, YF | 1 |
| Xie, HG | 1 |
| Sorich, MJ | 1 |
| Polasek, TM | 1 |
| Wiese, MD | 1 |
| Doğan, A | 1 |
| Icli, A | 1 |
| Varol, E | 1 |
| Erdogan, D | 1 |
| Salari, K | 1 |
| Watkins, H | 1 |
| Ashley, EA | 1 |
| Isordia-Salas, I | 1 |
| Olalde-Román, MJ | 1 |
| Santiago-Germán, D | 1 |
| de la Peña, NC | 1 |
| Valencia-Sánchez, JS | 1 |
| Lala, A | 1 |
| Berger, JS | 1 |
| Sharma, G | 1 |
| Hochman, JS | 1 |
| Scott Braithwaite, R | 1 |
| Ladapo, JA | 1 |
| Carlquist, JF | 1 |
| Knight, S | 1 |
| Horne, BD | 1 |
| Huntinghouse, JA | 1 |
| Rollo, JS | 1 |
| Muhlestein, JB | 1 |
| May, H | 1 |
| Anderson, JL | 1 |
| SoRelle, R | 1 |
| Ziegler, S | 1 |
| Schillinger, M | 1 |
| Funk, M | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Mlekusch, W | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Minar, E | 1 |
| Brunner, M | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Potapov, EV | 1 |
| Hetzer, R | 1 |
| Braunwald, E | 1 |
| Angiolillo, D | 1 |
| Bates, E | 1 |
| Berger, PB | 1 |
| Bhatt, D | 1 |
| Cannon, CP | 1 |
| Furman, MI | 1 |
| Gurbel, P | 1 |
| Michelson, AD | 1 |
| Peterson, E | 1 |
| Wiviott, S | 1 |
7 reviews available for ticlopidine and Genetic Predisposition
| Article | Year |
|---|---|
Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Blood Platelets; Clop | 2013 |
Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Genetic Predisposition to Disease; Genetic Variation; | 2017 |
Recent developments in the use of antiplatelet agents to prevent cardiovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding C | 2011 |
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Predisposition to Dise | 2012 |
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Association S | 2012 |
Personalized medicine: hope or hype?
Topics: Anticoagulants; Cardiovascular Diseases; Clopidogrel; Genetic Predisposition to Disease; Genetic Tes | 2012 |
Investigating the mechanisms of hyporesponse to antiplatelet approaches.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Genetic Predispos | 2008 |
3 trials available for ticlopidine and Genetic Predisposition
| Article | Year |
|---|---|
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Pre | 2016 |
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Comorbidity; Coronary Artery Disease; Cytokines; Female; Genetic Predisposition to Dise | 2012 |
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP3A; Drug Resistance; | 2012 |
33 other studies available for ticlopidine and Genetic Predisposition
| Article | Year |
|---|---|
The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; DNA Methylation; Drug Resistance; | 2017 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Dec | 2018 |
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition | 2018 |
PXR polymorphisms have impact on the clinical efficacy of clopidogrel in patients undergoing percutaneous coronary intervention.
Topics: Aged; Carboxylic Acids; China; Chromatography, High Pressure Liquid; Female; Genetic Predisposition | 2018 |
Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study.
Topics: Acute Coronary Syndrome; Biomarkers; Blood Platelets; Cause of Death; Clopidogrel; Equilibrative Nuc | 2019 |
Two common mutations within CYP2C19 affected platelet aggregation in Chinese patients undergoing PCI: a one-year follow-up study.
Topics: Alleles; Aspirin; Blood Platelets; China; Cytochrome P-450 CYP2C19; Female; Genetic Association Stud | 2019 |
Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients.
Topics: Aged; Aryldialkylphosphatase; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Female; G | 2013 |
[Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary artery disease].
Topics: Antigens, Human Platelet; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Diseas | 2013 |
Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Fibrinogen; Genetic Predisposition to Disease | 2014 |
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; DNA Methylation; Drug Resistance; Female; Genetic Associ | 2014 |
Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Biomarkers; Chemokine | 2016 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy.
Topics: Adult; Aged; Alleles; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP2C | 2016 |
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
Topics: Aged; Alleles; Asian People; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; G | 2015 |
P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
Topics: Acute Lung Injury; Animals; Blood Platelets; Clopidogrel; Cytokines; Genetic Predisposition to Disea | 2016 |
Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel.
Topics: Aged; Blood Platelets; Case-Control Studies; Chromatography, High Pressure Liquid; Clopidogrel; Coro | 2016 |
Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3.
Topics: Adenosine Diphosphate; Animals; Carrier Proteins; Cat Diseases; Cats; Clopidogrel; Gene Expression R | 2016 |
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
Topics: Alleles; Antidepressive Agents; Antifungal Agents; Chemical and Drug Induced Liver Injury; Chromosom | 2017 |
Cardiovascular disease gets personal.
Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Genetic Pred | 2009 |
Familial Takayasu's arteritis in female siblings.
Topics: Adult; Aorta, Thoracic; Aspirin; Clopidogrel; Family Health; Female; Genetic Predisposition to Disea | 2011 |
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Cardiovascular Ag | 2011 |
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clinical Trials Data Monitoring Commit | 2011 |
[Factors determining clinical effectiveness of clopidogrel and prognosis of patients with stable ischemic heart disease].
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Female; Follow-U | 2011 |
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; | 2011 |
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2011 |
CYP2C19 gene variants cut-off levels for on-clopidogrel platelet aggregation.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Dr | 2012 |
Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
Topics: Aged; Aged, 80 and over; Amplified Fragment Length Polymorphism Analysis; Angioplasty, Balloon, Coro | 2011 |
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
Topics: Adolescent; Anticoagulants; Aspirin; Cholesterol Ester Transfer Proteins; Clopidogrel; Coronary Angi | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Comp | 2013 |
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cass | 2013 |
Clopidogrel resistance marks recurrent risks.
Topics: Aged; Bibliometrics; Cardiology; Clopidogrel; Cohort Studies; Coronary Restenosis; Drug Resistance; | 2004 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
Impact of PlA polymorphism of platelet GP IIb/IIIa receptors on clinical course during long-term LVAD support is independent of type of LVAD.
Topics: Anticoagulants; Antigens, Human Platelet; Aspirin; Clopidogrel; Equipment Design; Genetic Predisposi | 2006 |